Owing to its central role in cancer cell pathology, malignant cells often overexpress TfR, and this increased expression may be associated with poor prognosis in various cancer types.[228] The elevated expression of TfR on malignant cells, along with its extracellular accessibility, internalization ability, and central role in cancer cell pathology, makes this receptor an attractive target for targeted delivery.[227] Several studies have revealed that TfR ligand‐modified NMs promote the accumulation of the modified NMs in LC cells, enhancing drug efficacy. The gene discussed is TFRC; the disease is cancer.